Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Young Iee Park"'
Autor:
Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7784-7794 (2023)
Abstract Background In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first‐line chemotherapy in advanced gastric cancer. Patients and Methods Patients with m
Externí odkaz:
https://doaj.org/article/282b0a8fa02d4899b6eff2f3eaf72e70
Autor:
Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, Kun‐Huei Yeh, Changhoon Yoo, Young Seon Hong, Young Iee Park, Sung Hyun Yang, Dong Bok Shin, Dae Young Zang, Won Ki Kang, Ik‐Joo Chung, Yeul Hong Kim, Baek‐Yeol Ryoo, Byung‐Ho Nam, Young Soo Park, Yoon‐Koo Kang
Publikováno v:
Cancer Medicine. 12:7784-7794
In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first-line chemotherapy in advanced gastric cancer.Patients with metastatic gastric or gastroesophageal juncti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::984b9e0e254e596850f43dc0af1f46dd
https://doi.org/10.1002/cam4.5536
https://doi.org/10.1002/cam4.5536
Autor:
Hyung-Don Kim, Jong Seok Lee, Young Soo Park, Jeong Hwan Yook, Sung Hoon Noh, Young-Kyu Park, Young-Woo Kim, Sang Cheul Oh, Jong Gwang Kim, Min-Hee Ryu, Jae-Ho Cheong, HyunKi Kim, Joon Seok Lim, Jae-Hyuk Lee, Suk Hee Heo, Jin Young Kim, Mi Hwa Heo, Young Iee Park, In-Ho Kim, Yoon-Koo Kang
Publikováno v:
Gastric Cancer. 25:1039-1049
In this post hoc analysis of the PRODIGY study, we aimed to investigate factors associated with survival outcomes and provide evidence for designing optimal perioperative treatment strategies for gastric cancer patients receiving neoadjuvant chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86882208dbc477b5a507aa3cded62cfb
https://doi.org/10.1007/s10120-022-01325-6
https://doi.org/10.1007/s10120-022-01325-6
Autor:
Sang-Hee Cho, Min-Hee Ryu, Keun-Wook Lee, Ho-Suk Oh, Sook Ryun Park, Hye Sook Han, Jin Won Kim, Byung-Ho Nam, Bong-Gun Seo, Ik-Joo Chung, Yoon-Koo Kang, Jae-Cheol Jo, Kyung Hee Lee, Hyo Rak Lee, Young Iee Park
Publikováno v:
Gastric Cancer. 24:156-167
In East Asia, S-1 plus cisplatin (SP) is one of the standard first-line chemotherapy regimens for metastatic or recurrent gastric cancer (MRGC). Oxaliplatin is generally less toxic and more convenient to administer than cisplatin. This was a multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653b80a240f71870d8e44dd7dbe84835
https://doi.org/10.1007/s10120-020-01101-4
https://doi.org/10.1007/s10120-020-01101-4
Autor:
Sang Soo Eom, Wonyoung Choi, Bang Wool Eom, Sin Hye Park, Soo Jin Kim, Young Il Kim, Hong Man Yoon, Jong Yeul Lee, Chan Gyoo Kim, Hark Kyun Kim, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim, Young Iee Park, Keun Won Ryu
Publikováno v:
Journal of gastric cancer. 22(1)
Countries differ in their treatment expertise and research results regarding gastric cancer; hence, treatment guidelines are diverse based on evidence and medical situations. A comprehensive and comparative review of each country's guidelines is impe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ca8ce23c66b9bba53e498dba59a49e
https://pubmed.ncbi.nlm.nih.gov/35425651
https://pubmed.ncbi.nlm.nih.gov/35425651
Autor:
Jin Soo Kim, Jae Yong Cho, Na Mi Lee, Yung-Jue Bang, Dae Young Zang, Tae Yong Kim, Yeul Hong Kim, Eun Kee Song, Hye Sook Han, Se Hoon Park, Keun Wook Lee, Young Iee Park, Soo A. Jung, Sun Young Rha, Kyung Hun Lee
Publikováno v:
Gastric Cancer. 22:1206-1214
Background Poziotinib (HM781-36B) is an irreversible pan-HER tyrosine kinase inhibitor which targets EGFR, HER2, and HER4. This prospective, multicenter, open-label, phase I/II study determined the maximum tolerated dose (MTD) and evaluated the safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f3f2d13418c33e7681aded84e3e126
https://doi.org/10.1007/s10120-019-00958-4
https://doi.org/10.1007/s10120-019-00958-4
Publikováno v:
Pharmacogenetics and Genomics. 28:23-30
This study investigated the efficacy and safety of S-1 versus capecitabine in elderly patients with metastatic gastric cancer (MGC), and examined the association between cytochrome P450 2A6 (CYP2A6) polymorphisms and treatment outcomes.MGC patients 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a56720bf93ffe04baa0bf92a19e982c
https://doi.org/10.1097/fpc.0000000000000320
https://doi.org/10.1097/fpc.0000000000000320
Publikováno v:
Gastric Cancer. 21:453-463
Some clinicopathological variables are known to influence the survival of patients with advanced gastric cancer. A comprehensive model based on these factors is needed for prediction of an individual’s survival and appropriate patient counseling. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cfa624e294e6d19a4396ac8107725a
https://doi.org/10.1007/s10120-017-0756-z
https://doi.org/10.1007/s10120-017-0756-z
Autor:
Young Suk Park, Kim Kyu Pyo, Ik Joo Chung, Sang-Hee Cho, Keun-Wook Lee, Kyu Taeg Lee, Dong Bok Shin, Ho Suk Oh, Jung Hun Kang, Ji Won Kim, Young Iee Park, Sook Ryun Park, Dae Young Zang, Jee Hyun Kim, Myung Ah Lee, Byung-Ho Nam, Hye Sook Han, Hye Jin Kang, Tae Won Kim, Sun Young Kim, Eun Kee Song, Jeong Eun Kim, Yong Sang Hong, Ju Hyun Lee
Publikováno v:
The Oncologist. 22:293-303
BACKGROUND Irinotecan-based chemotherapy is a standard backbone of therapy in patients with metastatic colorectal cancer (CRC) or gastric cancer (GC). However, there is still a paucity of information concerning the efficacy and safety of irinotecan-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c4c2b11c70517fc47f69a8b75c6508
https://doi.org/10.1634/theoncologist.2016-0166
https://doi.org/10.1634/theoncologist.2016-0166
Autor:
Jin Won Kim, Bum Jun Kim, Sook Ryun Park, Hye Sook Han, Mi-Jung Kim, Young Iee Park, Keun-Wook Lee
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen. Materials and Methods Patients with progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a26ee107b2948a834c6122ef78f6615
http://europepmc.org/articles/PMC5512362
http://europepmc.org/articles/PMC5512362